bioAffinity Technologies, Inc.
bioAffinity Technologies develops noninvasive diagnostic laboratory tests for lung diseases using flow cytometry and automated analysis informed by machine learning. Its first commercial test, CyPath® Lung, analyzes sputum to help physicians assess patients at high risk of lung cancer, including those with pulmonary nodules. The test is performed by its wholly owned subsidiary PPLS, a clinical laboratory, and is sold to physicians for use in patient assessment. The company also has companion diagnostic tests for asthma and chronic obstructive pulmonary disease under development, and conducts cancer therapeutic research through its wholly owned subsidiary OncoSelect® Therapeutics, LLC. bioAffinity Technologies makes money from diagnostic testing services, including CyPath® Lung testing. It conducts research in laboratories at PPLS and in leased laboratory space at The University of Texas at San Antonio. The company is headquartered in San Antonio, Texas.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BIAF in the last 30 days.
See all $BIAF insider activity →bioAffinity Technologies (BIAF) reported 235 CyPath Lung tests in October, a 29% increase from last year. The company attributes growth to expanded physician adoption and commercial efforts. CyPath Lung uses AI to assess lung cancer risk, with 92% sensitivity and 87% specificity in trials. BIAF is also advancing R&D for asthma, COPD, and skin cancer treatments.
bioAffinity Technologies reported Q3 2026 revenue of $1.1M and a net loss of $5.3M. CyPath Lung test sales doubled year-to-date, with testing revenue up 79%. The company had $2.6M in cash at quarter-end. Operating loss widened to $3.5M from $2.3M a year earlier. Physician orders and test reports increased significantly, and the company expanded its distribution network and research collaborations.
bioAffinity Technologies reported growth in CyPath® Lung testing volume and 9M revenue, but total revenue declined due to discontinued pathology services. The company faced increased losses, higher cash burn, and expressed concerns about its ability to continue as a going concern, indicating a need for additional financing.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning BIAF (bioAffinity Technologies, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent BIAF coverage spans earnings, technology and financial news.
The surge in test volume signals expanding market adoption and potential revenue upside for BioAffinity.
Quarterly results show continued revenue growth in CyPath Lung testing but worsening losses and a sharp cash decline, raising near-term financing and execution risk.
The new quarterly filing highlights worsening financial health, likely prompting sell pressure.
Strong top‑line growth and expanding physician adoption suggest upward price pressure.
The expansion into COPD and asthma could broaden the addressable market and drive revenue growth, while recent strong growth and reimbursement news may boost investor sentiment.
AlphAI scores every news story that mentions BIAF with an AI model for sentiment and relevance, and aggregates insider trades from bioAffinity Technologies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
bioAffinity Technologies (BIAF) reported 235 CyPath Lung tests in October, a 29% increase from last year. The company attributes growth to expanded physician adoption and commercial efforts. CyPath Lung uses AI to assess lung cancer risk, with 92% sensitivity and 87% specificity in trials. BIAF is also advancing R&D for asthma, COPD, and skin cancer treatments.
bioAffinity Technologies reported Q3 2026 revenue of $1.1M and a net loss of $5.3M. CyPath Lung test sales doubled year-to-date, with testing revenue up 79%. The company had $2.6M in cash at quarter-end. Operating loss widened to $3.5M from $2.3M a year earlier. Physician orders and test reports increased significantly, and the company expanded its distribution network and research collaborations.
bioAffinity Technologies reported growth in CyPath® Lung testing volume and 9M revenue, but total revenue declined due to discontinued pathology services. The company faced increased losses, higher cash burn, and expressed concerns about its ability to continue as a going concern, indicating a need for additional financing.
bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath ® Lung Commercialization CyPath ® Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing rev
bioAffinity Technologies, a biotech company, reported 200% year-over-year growth in Q2, driven by its noninvasive lung cancer detection test. The test uses sputum samples and AI to analyze the lung microenvironment. The company plans to expand its diagnostic platform into COPD and asthma, and has partnerships with AB Medical and Pictor for market access and technology development.
bioAffinity Technologies (BIAF) will present CyPath Lung at CHEST 2026, highlighting its use in lung cancer risk assessment and new asthma/COPD inflammation test research. The company reported 92% sensitivity, 87% specificity, and 99% NPV in prior trials. The Medical and Scientific Advisory Board will discuss expansion and R&D programs.
bioAffinity Technologies will present data at CHEST 2026 on its investigational sputum test, which can detect lung inflammation protein biomarkers linked to asthma and COPD drug targets. The test, not yet FDA cleared, measures biomarkers like TSLP and IL-5, building on the company's CyPath Lung platform. According to the SEC filing, the test may help identify patients for biologic therapies with further validation.
bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026 Findings report on ability to measure cellular and soluble inflammatory
bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 News Release bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules SAN ANTONIO, Texas (October 8, 2026) – bioAffinity Technologies, Inc .
bioAffinity Technologies (NASDAQ: BIAF) raised $4M via a registered direct offering and private placement, selling shares and warrants at $6.122 each. Proceeds will support working capital and lung cancer test sales. WallachBeth Capital acted as placement agent. Closing expected October 9, 2026.
